|[August 21, 2013]
DNAnexus Appoints Arthur Cole as General Manager of Europe
MOUNTAIN VIEW, Calif. --(Business Wire)--
DNAnexus (News - Alert), Inc., a pioneer in cloud-based DNA data management and
analysis solutions, today announced the appointment of Arthur Cole, PhD,
as General Manager, Europe. Cole is a senior commercial executive who
brings more than three decades of healthcare industry experience to
DNAnexus. Based in the United Kingdom, Cole will be responsible for the
company's rapidly growing marketing, sales and business development
activities across the European market.
"Arthur's distinguished leadership career with commercial healthcare
organizations in Europe makes him a clear choice for this vital role,"
said Richard Daly, CEO of DNAnexus. "He is well respected within the
European pharmaceutical, biotechnology and diagnostics markets and his
experience will be an important asset to the company as we expand our
presence in the region."
A longtime member of the European healthcare industry, Cole joins
DNAnexus from management consulting firm Debon Strategic Partners, where
he was a managing partner providing strategic analysis, business
planning and interim management services to biotechnology and molecular
diagnostics companies. Prior, he was executive vice president at Visible
Genetics where he led the company in Europe to a dominant position in
DNA sequence-based HIV antiretrovial drug resistance testing before the
company was acquired by Bayer Diagnostics. He also held a number of
senior leadership positions during more than 13 years with Pharmacia
Biotech including managing the company's global commercial operations
and leading the strategic planning process during a turn-around period
in the company's history. Cole earned his PhD in biochemistry from
Charing Cross Hospital Medical School, University of London.
"The use of genomic data in clinical settings is an exciting medical
advance that has created a pressing need for specialized technology
infrastructures that can manage the demands of increasingly
sophisticated data analysis pipelines," said Cole. "DNAnexus excels in
combining cloud computing infrastructure with scalable systems design
and advanced bioinformatics, and I look forward to working with them to
bring this technology to the many European organizations engaged in
DNA-based medicine and biotechnology."
The DNAnexus platform is a configurable API-based infrastructure that
enables genomic R&D enterprises to easily expand their data analysis and
storage infrastructure needs into the cloud and transform large capital
expenditures into transparent operating expenses. Using DNAnexus, labs
of any size can build and run their data analysis apps and workflows
from anywhere in the world and work securely and compliantly with
research and clinical collaborators.
For more information, please visit www.DNAnexus.com.
DNAnexus is powering the genomics revolution with a technology platform
that combines cloud computing infrastructure with scalable systems
design and advanced bioinformatics. The DNAnexus team is made up of
experts in software, computational biology, and genetics who are on a
mission to establish the DNAnexus platform as the core of a growing
ecosystem of scientific and clinical research and diagnostic efforts in
personalized medicine. For more information please visit https://dnanexus.com.
[ Back To Technology News's Homepage ]